We're not going to have them for biosimilars. This reform will take the five to eight year time frame to bring a biosimilar to market and cut it in half. It will also save companies about $100 million in their development costs. That'll take the cost down from 200 million down to 100 million or 250 million down to 150 million. I'm giving you real numbers that companies have shared with me on their costs. (12:56–13:03)
CLAIM
Asserts that FDA reform will save companies about $100 million in development costs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
_(cropped).png)